Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…

The tau theory in Alzheimer’s disease took a hit today after TauRx, one of the leading companies researching this hypothesis, saw its drug when used with…

We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

This year will be the year of the woman exec in biotech, no doubt about it.

Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal…

Bristol-Myers Squibb is really racking up the cancer pacts as today it pens another deal for its PD-1 checkpoint inhibitor Opdivo (nivolumab)--this time to be…

AstraZeneca and partner Moderna Therapeutics are heading to the lab for the first time together with their experimental cardiometabolic drug AZD8601.

The FDA has granted breakthrough therapy status to J&J and Genmab's Darzalex as a second-line treatment for multiple myeloma, positioning it for a…